- Annual Report: Achievements Building a Healthier Future
- Elevating Education Across the Diagnostic Pathway
News
Marcy l’Étoile, France – May 29, 2026 – bioMérieux, a world leader in the field of in vitro diagnostics, announces a strategic investment of more than €250 million to build a new manufacturing facility in France (La Balme-les-Grottes, Isère) dedicated to the production of PCR tests from its BIOFIRE® range. The project is expected to create approximately 400 jobs over time. This new facility will help secure the supply of essential diagnostic solutions for the European market while strengthening the resilience of healthcare systems in the face of infectious diseases.
Swipe to discover more
-
First-Quarter 2026 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31, 2026. Consolidated sales totaled €984 million in the first quarter of 2026. -
Always consider sepsis in the context of infection.
Patient associations across the globe are actively engaged in promoting this critical message to both healthcare professionals and the broader public. We met with Dr Rafael Moraes from ILAS, Melissa Mead from The UK Sepsis Trust and Thomas Heymann from Sepsis Alliance to learn more about their actions. -
Preserving the planet to protect health: our commitments and progress
Preserving the planet to protect health: our commitments and progress
Fully aware of today’s climate and environmental challenges, we are taking action to reduce the footprint of our activities, optimize the use of resources, and design increasingly responsible solutions. Since 2019, we have been committed to an ambitious environmental trajectory. Here is an overview of the concrete, measurable, and sustainable actions implemented by our teams around the world.
Enabling Decision-Making
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19